FDMT Q3 2025 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90,000+2900.0% YoY

Gross Profit

-$47M-52386.7% margin

Operating Income

-$61M-67983.3% margin

Net Income

-$57M-63195.6% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+500.0%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$46M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$424M

Total Liabilities

$55M

Stockholders' Equity

$369M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90,000	$3,000	+2900.0%
Gross Profit	-$47M	$3,000	-1571700.0%
Operating Income	-$61M	-$51M	-19.7%
Net Income	-$57M	-$44M	-29.7%

Revenue Segments

Collaboration And License Revenue

$90,000100%